Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Zentalis Pharmaceuticals Inc
Cash from Financing Activities
Zentalis Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
|
Cash from Financing Activities
$261m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
94%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Zentalis Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
261m
USD
Based on the financial report for Dec 31, 2023, Zentalis Pharmaceuticals Inc's Cash from Financing Activities amounts to 261m USD.
What is Zentalis Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
94%
Over the last year, the Cash from Financing Activities growth was 0%. The average annual Cash from Financing Activities growth rates for Zentalis Pharmaceuticals Inc have been -10% over the past three years , 94% over the past five years .